Literature DB >> 26116340

Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.

Eelke Lucie Anne Toxopeus1, Daan Nieboer2, Joel Shapiro3, Katharina Biermann4, Ate van der Gaast5, Carolien M van Rij6, Ewout Willem Steyerberg2, Joseph Jan Baptiste van Lanschot3, Bas Peter Louis Wijnhoven3.   

Abstract

BACKGROUND: A pathologically complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) is seen in 30% of the patients with oesophageal cancer. The aim is to identify patient and tumour characteristics associated with a pCR and to develop a nomogram for the prediction of pCR. PATIENTS AND METHODS: Patients who underwent nCRT followed by surgery were identified and response to nCRT was assessed according to a modified Mandard classification in the resection specimen. A model was developed with age, gender, histology and location of the tumour, differentiation grade, alcohol use, smoking, percentage weight loss, Charlson Comorbidity Index (CCI), cT-stage and cN-stage as potential predictors for pCR. Probability of pCR was studied via logistic regression. Performance of the prediction nomogram was quantified using the concordance statistic (c-statistic) and corrected for optimism.
RESULTS: A total of 381 patients were included. After surgery, 27.6% of the tumours showed a pCR. Female sex, squamous cell histology, poor differentiation grade, and low cT-stage were predictive for a pCR with a c-statistic of 0.64 (corrected for optimism).
CONCLUSION: A nomogram for the prediction of pathologically complete response after neoadjuvant chemoradiotherapy was developed, with a reasonable predictive power. This nomogram needs external validation before it can be used for individualised clinical decision-making.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemoradiotherapy; Oesophageal cancer; Prediction of response; Surgery

Mesh:

Year:  2015        PMID: 26116340     DOI: 10.1016/j.radonc.2015.04.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma.

Authors:  M L Sánchez de Molina; C Díaz Del Arco; P Vorwald; D García-Olmo; L Estrada; M J Fernández-Aceñero
Journal:  Clin Transl Oncol       Date:  2017-06-26       Impact factor: 3.405

2.  The emerging field of radiomics in esophageal cancer: current evidence and future potential.

Authors:  Peter S N van Rossum; Cai Xu; David V Fried; Lucas Goense; Laurence E Court; Steven H Lin
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

3.  Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.

Authors:  Wenwu He; Tianqin Mao; Jiaxin Yan; Xuefeng Leng; Xuyang Deng; Qin Xie; Lin Peng; Qiong Liao; Marco Scarpa; Yongtao Han
Journal:  Ann Transl Med       Date:  2021-04

4.  Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.

Authors:  E R C Hagens; M L Feenstra; W J Eshuis; M C C M Hulshof; H W M van Laarhoven; M I van Berge Henegouwen; S S Gisbertz
Journal:  Br J Surg       Date:  2020-02-03       Impact factor: 6.939

5.  Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.

Authors:  Eelke L A Toxopeus; Femke M de Man; Nanda Krak; Katharina Biermann; Annemieke J M Nieuweboer; Lena E Friberg; Esther Oomen-de Hoop; Jan J B van Lanschot; Joel Shapiro; Bas P L Wijnhoven; Ron H J Mathijssen
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

6.  The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  G W van Pelt; J A Krol; I M Lips; F P Peters; D van Klaveren; J J Boonstra; W O de Steur; R A E M Tollenaar; A Farina Sarasqueta; W E Mesker; M Slingerland
Journal:  Clin Transl Radiat Oncol       Date:  2019-11-27

7.  Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.

Authors:  Yingjia Wu; Jinbin Chen; Lei Zhao; Qiaoqiao Li; Jinhan Zhu; Hong Yang; Suping Guo; Mian Xi
Journal:  Cancer Res Treat       Date:  2020-09-04       Impact factor: 4.679

8.  Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery.

Authors:  Yonghe Chen; Dan Liu; Jian Xiao; Jun Xiang; Aihong Liu; Shi Chen; Junjie Liu; Xiansheng Hu; Junsheng Peng
Journal:  Gastroenterol Res Pract       Date:  2021-07-28       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.